Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: a Mutation landscape of pre-invasive (AAH/AIS/MIA, left) and invasive adenocarcinoma (right) samples. b MAP2K1 mutations identified in the study cohort. c MAP2K1 mutations identified in our previous study of 98 pre-invasive and 99 invasive adenocarcinoma samples. d Comparison of tumor mutation burden between samples in this cohort and TCGA cohorts. e Landscape of somatic copy number alterations (SCNAs) in this study cohort, with pre-invasive samples at the top and invasive samples at the bottom. f Co-mutational status, showing the mutual exclusivity and co-occurrence of major oncogenes and tumor suppressor genes. Statistical significance was assessed using Fisher’s exact test.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques: Mutagenesis, Comparison

Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques: In Vitro, In Vivo, Western Blot, Negative Control, Staining

Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: Analysis of 1008 LUAD samples identified the MAP2K1 E102–I103 deletion as a potential driver of LUAD initiation. LUAD progression was associated with increased genomic instability, including a higher tumor mutational burden, increased SCNA burden, and increased structural variations. Furthermore, patients with site-specific recurrences exhibited distinct genomic and transcriptomic profiles.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques:

Journal: Journal of Dental Sciences

Article Title: Overexpression of sprouty 1 protein in human oral squamous cell carcinogenesis

doi: 10.1016/j.jds.2020.07.013

Figure Lengend Snippet: Western blot analyses: phosphor-ERK and total-ERK in human oral cancer cell lines as compared with a primary culture of normal oral mucosa (HOK). Upregulation of phosphor-ERK (normalized to total-ERK) in OECM1 and Ca922 cell lines as compared with HOK, and a slightly decreased expression in SAS as compared with HOK. Results were quantified using densitometric analysis, normalized to the level of β-actin, and expressed as a fold change relative to the normal oral mucosa. Bars represent means ± standard deviation of the mean (∗ P < 0.05). A representative result of three independent experiments is shown.

Article Snippet: Further, samples were analyzed using 10% SDS-PAGE (Sigma-Aldrich) gels, and the proteins were transmitted onto a PVDF membrane (Sigma-Aldrich) using Bio-Rad's transblot with primary antibodies against phosphor-ERK (Boster Biological Technology, CA, USA; Cat. No. P00104; 1:1000) and total-ERK (Boster Biological Technology; Cat. No. P00104; 1:1000), with species specificity for human tissues and an observed molecular weight of 42–44 kDa; and β-actin (Sigma-Aldrich; 1:1000), followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Sigma-Aldrich; 1:5000).

Techniques: Western Blot, Expressing, Standard Deviation

Journal: Bioscience trends

Article Title: Mongolian Medicine echinops prevented postmenopausal osteoporosis and induced ER/AKT/ERK pathway in BMSCs.

doi: 10.5582/bst.2018.01046

Figure Lengend Snippet: Figure 6. Effects of echinops-containing serum on expressions of ERα, ERβ, AKT, p-AKT, ERK, and P-ERK in BMSCs. BMSCs were treated with Echniops-containing serum that collected from rats administrated with 16.26 (low), 32.5 (middle), and 65 (high) mg/kg echinops. (A) ERα mRNA. (B) ERβ mRNA. (C) ERα, ERβ, AKT, p-AKT, ERK, and p-ERK. (D) Quantification of western bolts. *p < 0.05, **p < 0.01 vs. control.

Article Snippet: The membrane was incubated with 5% non-fat milk for 30 min, and incubated with primary antibodies ERα (1:2,000), ERβ (1:4,000), AKT (1:1,500), p-AKT (1:1,000), ERK (1:1,000), p-ERK (1:2,000), and GAPDH (1:10,000) antibody at room temperature for 1 h, and then incubated with HRP goat anti-rabbit IgG secondary antibody (1:20,000, BOSTER, China) at room temperature for 40 min.

Techniques: Western Blot, Control